Jan 22, 2025, 11:08
Akhil Santhosh: TBCRC 048 – good activity for olaparib in BRCA1/2 advanced breast cancer
Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, posted on X:
“TBCRC 048: good activity for olaparib in somatic BRCA1/2 altered advanced breast cancer patients.
- n=30
- ORR 37%, CBR 53%, mPFS7.2months, DOR-12.4m.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 22, 2025, 11:09
Jan 22, 2025, 11:03
Jan 22, 2025, 10:59
Jan 22, 2025, 10:40
Jan 22, 2025, 10:35